Skip to content
Peptide research

Noopept

Also known as GVS-111 · Omberacetam
Category
Brain & Cognition
Administration routes
Oral
Regulatory status
Not FDA-approved

What it is

Noopept is a synthetic dipeptide sold as a nootropic for memory and focus, active at doses roughly 1000 times lower than piracetam. Evidence for cognitive benefit is moderate, but neuroprotection, BDNF upregulation, and mood effects rest mainly on animal and mechanism studies, not confirmed human trials. Safety data beyond about 56 days does not exist. It is not an FDA-approved drug and is sold mainly as an unregulated research-grade or supplement product.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Cognitive enhancement at very low doses (~1000x more potent than piracetam)

    Medium

    Confirmed in animal studies; human evidence limited to small, unblinded Russian clinical trials.

  • Neuroprotection against amyloid-beta toxicity in Alzheimer's disease models

    Low

    Rodent and neuronal cell studies show protection against beta-amyloid toxicity; no human Alzheimer's trials yet.

  • Upregulation of BDNF and NGF in hippocampus and cortex (chronic treatment)

    Low

    Rat data show increased hippocampal NGF and BDNF expression and a smaller cortical BDNF increase after chronic treatment; this study did not assess human biomarkers.

Evidence limits

Evidence Level
Limited Clinical / Strong Preclinical

Clinical evidence for noopept includes several small studies. Among them is an open-label comparison (n=53) in patients with mild cognitive disorders, which showed improvements in cognition, mood, and anxiety with 56 days of treatment at 10mg BID. No placebo-controlled, double-blind trials have been published in English-language journals. Preclinical evidence is more extensive, with neuroprotective effects demonstrated in AD, ischemia, and excitotoxicity models. Almost all published studies originate from Russian laboratories at the Zakusov Institute. Noopept is registered as a nonprescription medicine in Russia.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(4)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Unknown long-term safety (limited data beyond 56 days)

    Moderate
  • Sleep disturbances (insomnia, vivid dreams)

    Low
  • Increased blood pressure

    Theoretical
  • Irritability and agitation

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.